安得能微脂體注射劑5 毫克毫升(Onivyde) 醫療科技評估報告 | 合法藥品大搜索

Read More

ONIVYDE(irinotecan微脂體注射劑)適用於轉移性胰腺癌，合併5-fluorouracil和leucovorin治療曾接受過gemcitabine的患者。 用法用量. 請勿以ONIVYDE取代其他含有 ... Read More

Irinotecan liposome injection, 5mg/mL. 主管機關許可適應症Onivyde (irinotecan 微脂體注射劑) 適用於轉移性胰腺癌，合併. 5-fluorouracil 和leucovorin 治療曾接受 ... Read More

由 JE Frampton 著作 · 2020 · 被引用 4 次 — Liposomal irinotecan (nal-IRI; Onivyde®; also known as pegylated liposomal irinotecan) has been developed with the aim of maximising ... Read More

ONIVYDE™ (irinotecan liposome injection), for intravenous use. Initial U.S. Approval: 1996. WARNING: SEVERE NEUTROPENIA and SEVERE DIARRHEA. Read More

由 FC Passero Jr 著作 · 2016 · 被引用 63 次 — The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based ... Read More

由 T Macarulla 著作 · 2019 · 被引用 7 次 — Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI ... Read More

由 LA Raedler 著作 · 被引用 1 次 — Irinotecan liposome injection is a topoisomerase-1 inhibitor encapsulated in a lipid bilayer liposome. Topoisomerase-1 is an enzyme that relieves torsional strain ... Read More

INDICATION. ONIVYDE® (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with ... Read More

ONIVYDE pegylated liposomal (irinotecan) must only be prescribed and administered to patients by healthcare professionals experienced in the use of anti-cancer ... Read More